Retrospective Comparative Study Of Recombinant Hunman Prourokinase And Urokinase In The Treatment Of Acute Deep Venous Thrombosis Of Lower Extremities By Catheter-directed Thrombolysis

Objective:The efficacy and safety of thrombolysis with recombinant human prourokinase and urokinase catheterization in the treatment of acute deep venous thrombosis of lower extremities were retrospectively analyzedMethods:According to the inclusion criteria and exclusion criteria,a total of 79 patients with acute lower extremity deep venous thrombosis were collected from October 2016 to February 2019 in the Department of Vascular surgery of Gansu Provincial people’s Hospital.According to the different thrombolytic drugs used in catheterization,the patients were divided into two groups:recombinant human prourokinase group(observation group,n=38)and urokinase group(control group,n=41).The thrombolytic efficiency was compared between groups according to the proportion of patients with grade 2 and 3 thrombolysis after 3 days of thrombolysis.After thrombolysis,the therapeutic effects of thrombolysis were compared between groups according to the clinical effective rate;The safety was compared between groups according to the occurrence of complicationsResults:There was no significant difference in age,course of disease,sex and general clinical data of diseased limbs between the two groups(P>0.05).After 3 days of thrombolysis,the proportion of patients with grade 2 and 3 thrombolysis in the observation group was 84.2%,while that in the control group was 63.4%(χ2=4.370,P=0.037).There was significant difference between the two groups(P<0.05).After thrombolysis,the clinical effective rate was 84.2%in the observation group and 80.5%in the control group(χ2=0.187,P=0.665).There was no difference between the two groups(P>0.05).The incidence of adverse reactions was 5.26%in the observation group and 9.76%in the control group(χ2=0.108,P=0.743).There was no difference between the two groups(P>0.05).Conclusion:Recombinant human prourokinase and urokinase catheterization thrombolysis showed good clinical efficacy and safety in the treatment of acute lower extremity deep venous thrombosis.The thrombolytic efficiency of recombinant human prourokinase is higher than that of urokinase.